Literature DB >> 16050517

Transmission of two Australian strains of murine cytomegalovirus (MCMV) in enclosure populations of house mice (Mus domesticus).

L N Farroway1, S Gorman, M A Lawson, N L Harvey, D A Jones, G R Shellam, G R Singleton.   

Abstract

To control plagues of free-living mice (Mus domesticus) in Australia, a recombinant murine cytomegalovirus (MCMV) expressing fertility proteins is being developed as an immunocontraceptive agent. Real-time quantitative PCR was used to monitor the transmission of two genetically variable field strains of MCMV through mouse populations after 25% of founding mice were infected with the N1 strain, followed by the G4 strain 6 weeks later. Pathogen-free wild-derived mice were released into outdoor enclosures located in northwestern Victoria (Australia). Of those mice not originally inoculated with virus, N1 DNA was detected in more than 80% of founder mice and a third of their offspring and similarly, G4 DNA was detected in 13% of founder mice and in 3% of their offspring. Thus, prior immunity to N1 did not prevent transmission of G4. This result is promising for successful transmission of an immunocontraceptive vaccine through Australian mouse populations where MCMV infection is endemic.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16050517      PMCID: PMC2870299          DOI: 10.1017/s0950268805003717

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  11 in total

1.  A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose.

Authors:  Yoshimi Tsuda; Christopher J Parkins; Patrizia Caposio; Friederike Feldmann; Sara Botto; Susan Ball; Ilhem Messaoudi; Luka Cicin-Sain; Heinz Feldmann; Michael A Jarvis
Journal:  Vaccine       Date:  2015-03-25       Impact factor: 3.641

Review 2.  MHC class I immune evasion in MCMV infection.

Authors:  Carmen M Doom; Ann B Hill
Journal:  Med Microbiol Immunol       Date:  2008-03-11       Impact factor: 3.402

3.  Laboratory strains of murine cytomegalovirus are genetically similar to but phenotypically distinct from wild strains of virus.

Authors:  L M Smith; A R McWhorter; L L Masters; G R Shellam; A J Redwood
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

4.  Transmissible vaccines whose dissemination rates vary through time, with applications to wildlife.

Authors:  Mark W Smithson; Andrew J Basinki; Scott L Nuismer; James J Bull
Journal:  Vaccine       Date:  2019-01-25       Impact factor: 3.641

5.  Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines.

Authors:  Suresh B Boppana; William J Britt
Journal:  Methods Mol Biol       Date:  2021

6.  A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.

Authors:  Yoshimi Tsuda; Patrizia Caposio; Christopher J Parkins; Sara Botto; Ilhem Messaoudi; Luka Cicin-Sain; Heinz Feldmann; Michael A Jarvis
Journal:  PLoS Negl Trop Dis       Date:  2011-08-09

7.  Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection.

Authors:  Andrea Marzi; Aisling A Murphy; Friederike Feldmann; Christopher J Parkins; Elaine Haddock; Patrick W Hanley; Matthew J Emery; Flora Engelmann; Ilhem Messaoudi; Heinz Feldmann; Michael A Jarvis
Journal:  Sci Rep       Date:  2016-02-15       Impact factor: 4.379

8.  Evaluating the promise of recombinant transmissible vaccines.

Authors:  Andrew J Basinski; Tanner J Varrelman; Mark W Smithson; Ryan H May; Christopher H Remien; Scott L Nuismer
Journal:  Vaccine       Date:  2017-12-24       Impact factor: 3.641

Review 9.  Self-disseminating vaccines for emerging infectious diseases.

Authors:  Aisling A Murphy; Alec J Redwood; Michael A Jarvis
Journal:  Expert Rev Vaccines       Date:  2015-11-02       Impact factor: 5.217

10.  Quantifying the effectiveness of betaherpesvirus-vectored transmissible vaccines.

Authors:  Tanner J Varrelman; Christopher H Remien; Andrew J Basinski; Shelley Gorman; Alec Redwood; Scott L Nuismer
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.